New Jersey Medical School (RU-NJMS) is the prime awardee of the FEND for TB Consortium program. Jerrold Ellner, MD (PI), David Alland, MD (Co-PI & Scientific Director), along with Susan Dorman (Co-PI & Clinical Director from the Medical University of South Carolina), direct the overall program with a consortium of experienced investigators and clinical sites, including advice/direction from NIAID (Dr. Karen Lacourciere, NIH Program Officer) and guidance from an External Advisory Committee. Rutgers benefits from its experience gained during the successful 7-year tenure of the NIH DMID-funded TB-Clinical Diagnostics Research Consortium (TB-CDRC), with an overlap in leadership, investigators and sites.

Rutgers also hosts the Data and Operations Management Center (DOMC) which currently coordinates and manages 12 NIH sponsored U01 and R01 projects involving human prospective clinical studies in 11 TB endemic countries. The DOMC is responsible for the set up of the clinical data collection, database management, and biorepository management for the FEND consortium.

The Analytic Laboratory Core is also located within Rutgers and provides a means for FEND-TB to independently test key assay parameters to ensure that assays are ready for evaluation at FEND-TB Clinical study sites.